High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma

被引:1
作者
Zhang, Can [1 ]
Zhu, Xinghua [2 ]
Li, Yong [1 ]
Shao, Jia [1 ]
Xu, Haibo [1 ]
Chen, Lei [1 ]
Dan, Youli [3 ]
Jin, Hua [4 ]
He, Aiqin [1 ]
机构
[1] Nantong Univ, Dept Gynecol Oncol, Affiliated Tumor Hosp, 30 Tongyang North Rd, Nantong 226300, Peoples R China
[2] Nantong Univ, Dept Pathol, Affiliated Tumor Hosp, Nantong, Peoples R China
[3] Med Coll Nantong Univ, Nantong, Peoples R China
[4] Nantong Univ, Canc Res Ctr Nantong, Affiliated Tumor Hosp, Nantong, Peoples R China
关键词
biomaker; early-stage cervical carcinoma; nomogram; prognosis; PYK2; FOCAL ADHESION KINASE; HEPATOCELLULAR-CARCINOMA; FAK INHIBITOR; PHASE-I; METASTASIS; PF-562,271; GROWTH; ACTIVATION; VS-6063; SAFETY;
D O I
10.1097/MD.0000000000031178
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Proline-rich tyrosine kinase-2 (PYK2), also known as calcium dependent tyrosine kinase, regulates different signal transduction cascades that control cell proliferation, migration, and invasion. However, the role of PYK2 in cervical cancer remains to be elucidated. The current study retrospectively included 134 patients with cervical cancer from December 2007 to September 2014. PYK2 expression was detected in tissue microarray and cervical cancer cell lines. Statistical analysis was performed to evaluate its clinicopathological significance. Small interfering RNA (siRNA) was employed to suppress endogenous PYK2 expression in cervical cancer cells to observe the biological function. PYK2 expression was up-regulated in cervical cancer specimens compared with paired adjacent normal cervical tissue samples. Statistical analyses indicated that PYK2 expression might be an independent prognostic indicator for patients with early-stage cervical cancer. A nomogram model was constructed based on PYK2 expression and other clinicopathological risk factors, and it performed well in predicting patients survival. In cellular studies, down-regulation of PYK2 remarkably inhibited cellular proliferation, migration and invasion. PYK2 expression possessed the potential to serve as a novel prognostic marker in cervical cancer patients.
引用
收藏
页数:7
相关论文
共 30 条
  • [1] Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model
    Bagi, Cedo M.
    Christensen, James
    Cohen, Darrel P.
    Roberts, Walter G.
    Wilkie, Dean
    Swanson, Terri
    Tuthill, Theresa
    Andresen, Catharine J.
    [J]. CANCER BIOLOGY & THERAPY, 2009, 8 (09) : 856 - 865
  • [2] Focal adhesion protein expression in human diffuse large B-cell lymphoma
    Bosch, Rosa
    Dieguez-Gonzalez, Rebeca
    Jose Moreno, Maria
    Gallardo, Alberto
    Novelli, Silvana
    Espinosa, Inigo
    Virtudes Cespedes, Maria
    Angel Pavon, Miguel
    Briones, Javier
    Granena, Albert
    Sierra, Jorge
    Mangues, Ramon
    Casanova, Isolda
    [J]. HISTOPATHOLOGY, 2014, 65 (01) : 119 - 131
  • [3] microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2
    Cao, Jie
    Liu, Jinkai
    Long, Jianyun
    Fu, Jing
    Huang, Liang
    Li, Jing
    Liu, Caifeng
    Zhang, Xianghua
    Yan, Yiqun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2017, 89 : 642 - 650
  • [4] Du QS, 2001, J CELL SCI, V114, P2977
  • [5] FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β
    Gao, Chenxi
    Chen, Guangming
    Kuan, Shih-Fan
    Zhang, Dennis Han
    Schlaepfer, David D.
    Hu, Jing
    [J]. ELIFE, 2015, 4
  • [6] Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma invitro and invivo
    Hu, Chuanzhen
    Chen, Xu
    Wen, Junxiang
    Gong, Liangzhi
    Liu, Zhuochao
    Wang, Jun
    Liang, Jing
    Hu, Fangqiong
    Zhou, Qi
    Wei, Li
    Shen, Yuhui
    Zhang, Weibin
    [J]. CANCER SCIENCE, 2017, 108 (07): : 1347 - 1356
  • [7] Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
    Infante, Jeffrey R.
    Camidge, D. Ross
    Mileshkin, Linda R.
    Chen, Eric X.
    Hicks, Rodney J.
    Rischin, Danny
    Fingert, Howard
    Pierce, Kristen J.
    Xu, Huiping
    Roberts, W. Gregory
    Shreeve, S. Martin
    Burris, Howard A.
    Siu, Lillian L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1527 - 1533
  • [8] Pyk2 and FAK regulate neurite outgrowth induced by growth factors and integrins
    Ivankovic-Dikic, I
    Grönroos, E
    Blaukat, A
    Barth, BU
    Dikic, I
    [J]. NATURE CELL BIOLOGY, 2000, 2 (09) : 574 - 581
  • [9] A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
    Jones, Suzanne F.
    Siu, Lillian L.
    Bendell, Johanna C.
    Cleary, James M.
    Razak, Albiruni R. A.
    Infante, Jeffrey R.
    Pandya, Shuchi S.
    Bedard, Philippe L.
    Pierce, Kristen J.
    Houk, Brett
    Roberts, W. Gregory
    Shreeve, S. Martin
    Shapiro, Geoffrey I.
    [J]. INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1100 - 1107
  • [10] PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein
    Kedan, Amir
    Verma, Nandini
    Saroha, Ashish
    Shreberk-Shaked, Michal
    Mueller, Anna-Katharina
    Nair, Nishanth Ulhas
    Lev, Sima
    [J]. CELL DEATH & DISEASE, 2018, 9